Abcellera Biologics is trading 11.40% up now at $7.72 after announcing that Phase 2 top-line data for ABCL635 will be released before the market opens on August 10, 2026.
- Investor call scheduled for 7:30 a.m. ET.
- Approximately 80-patient trial evaluates ABCL635 for menopause-related hot flashes, making the readout the key near-term catalyst.
- Recent earnings highlighted more than $675 million in liquidity.